Stevens Capital Management LP Acquires Shares of 1,232 West Pharmaceutical Services, Inc. $WST

Stevens Capital Management LP purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,232 shares of the medical instruments supplier's stock, valued at approximately $270,000.

• 3 Dividend Champions with room for dividend growth

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Zions Bancorporation National Association UT bought a new stake in West Pharmaceutical Services in the first quarter valued at about $25,000. Quarry LP bought a new position in West Pharmaceutical Services during the first quarter worth about $27,000. CVA Family Office LLC grew its position in shares of West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier's stock worth $44,000 after buying an additional 172 shares during the period. Cromwell Holdings LLC increased its stake in shares of West Pharmaceutical Services by 587.5% in the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier's stock valued at $48,000 after acquiring an additional 188 shares during the last quarter. Finally, Brooklyn Investment Group raised its position in shares of West Pharmaceutical Services by 83.3% in the 1st quarter. Brooklyn Investment Group now owns 275 shares of the medical instruments supplier's stock valued at $61,000 after acquiring an additional 125 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

WST has been the subject of a number of analyst reports. Zacks Research cut shares of West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 23rd. UBS Group upped their price objective on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, October 24th. TD Cowen began coverage on West Pharmaceutical Services in a report on Wednesday, October 29th. They set a "buy" rating and a $350.00 target price on the stock. Redburn Partners set a $311.00 price target on West Pharmaceutical Services in a research report on Monday, September 15th. Finally, Rothschild & Co Redburn initiated coverage on West Pharmaceutical Services in a research report on Monday, September 15th. They set a "buy" rating and a $311.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $349.20.

• What Factors Will Drive S&P 500 Performance This Year?

Read Our Latest Research Report on WST

West Pharmaceutical Services Stock Performance

WST opened at $270.99 on Friday. The company has a market capitalization of $19.50 billion, a price-to-earnings ratio of 40.15, a P/E/G ratio of 4.09 and a beta of 1.08. The business's 50-day moving average price is $269.34 and its two-hundred day moving average price is $243.58. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18.

• Healthcare Stocks With at Least 30 Years of Dividend Increases

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.29. The business had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.West Pharmaceutical Services's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Equities analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

• Five stocks we like better than West Pharmaceutical Services
• What is Short Interest? How to Use It
• MP Materials Stock Soared After Earnings—Here’s the Real Reason
• Best Aerospace Stocks Investing
• Why Palantir Slide May Be a Setup for a Long-Term Opportunity
• High Flyers: 3 Natural Gas Stocks for March 2022
• Attention Income Investors: This REIT Is on Sale

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in West Pharmaceutical Services Right Now?

Before you consider West Pharmaceutical Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.

While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here